Genmab has been granted a patent for antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The patent covers pharmaceutical compositions and therapeutic/diagnostic use in cancer therapy. The claim specifies nucleic acid constructs encoding antibodies with specific sequences for VH and VL regions. GlobalData’s report on Genmab gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Genmab, Personalized cancer vaccines was a key innovation area identified from patents. Genmab's grant share as of May 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies binding to 5t4 for cancer therapy
A recently granted patent (Publication Number: US11970544B2) discloses a nucleic acid construct encoding an antibody that binds to human 5T4, comprising specific heavy chain variable (VH) and light chain variable (VL) regions. The construct further includes an expression vector and a host cell for antibody production, along with a method for antibody purification. The antibody can be a monoclonal or full-length antibody, containing a human IgG1 constant region, and utilizing kappa or lambda light chain constant regions. Additionally, the patent covers the production of a bispecific antibody capable of binding to both human 5T4 and human CD3, involving specific antibody sequences and isomerization steps for obtaining the bispecific antibody.
Furthermore, the patent extends to nucleic acid constructs encoding bispecific antibodies with distinct antigen-binding regions for human 5T4 and human CD3, incorporating specific amino acid sequences and constant regions. The bispecific antibodies are designed to include a human IgG1 Fc region and light chain constant regions. The patent also encompasses expression vectors and host cells for producing these bispecific antibodies, along with a method for their purification. Overall, the patent provides a detailed framework for the development and production of antibodies targeting human 5T4 and human CD3, offering potential applications in therapeutic interventions and medical research.
To know more about GlobalData’s detailed insights on Genmab, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
